0001209191-21-012408.txt : 20210219
0001209191-21-012408.hdr.sgml : 20210219
20210219170024
ACCESSION NUMBER: 0001209191-21-012408
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210217
FILED AS OF DATE: 20210219
DATE AS OF CHANGE: 20210219
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: CURTIS GEOFFREY M.
CENTRAL INDEX KEY: 0001667903
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35238
FILM NUMBER: 21656866
MAIL ADDRESS:
STREET 1: C/O HORIZON PHARMA PLC
STREET 2: CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD
CITY: DUBLIN
STATE: L2
ZIP: L2 4
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Horizon Therapeutics Public Ltd Co
CENTRAL INDEX KEY: 0001492426
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: CONNAUGHT HOUSE, 1ST FLOOR
STREET 2: 1 BURLINGTON ROAD
CITY: DUBLIN
STATE: L2
ZIP: 4
BUSINESS PHONE: 011-353-1-772-2100
MAIL ADDRESS:
STREET 1: CONNAUGHT HOUSE, 1ST FLOOR
STREET 2: 1 BURLINGTON ROAD
CITY: DUBLIN
STATE: L2
ZIP: 4
FORMER COMPANY:
FORMER CONFORMED NAME: Horizon Pharma plc
DATE OF NAME CHANGE: 20140919
FORMER COMPANY:
FORMER CONFORMED NAME: HORIZON PHARMA, INC.
DATE OF NAME CHANGE: 20100520
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-02-17
0
0001492426
Horizon Therapeutics Public Ltd Co
HZNP
0001667903
CURTIS GEOFFREY M.
C/O HORIZON THERAPEUTICS PLC
CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD
DUBLIN
L2
4
IRELAND
0
1
0
0
EVP, Corporate Affairs, CCO
Ordinary Shares
2021-02-17
4
A
0
1571
0.00
A
87110
D
Ordinary Shares
2021-02-17
4
F
0
696
87.17
D
86414
D
Ordinary Shares
420
I
By spouse
Performance Restricted Stock Units (PSUs)
2021-02-17
4
A
0
3144
0.00
A
Ordinary Shares
3144
3144
D
Performance Restricted Stock Units (PSUs)
2021-02-17
4
A
0
11610
0.00
A
Ordinary Shares
11610
11610
D
On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 17, 2021, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2022 and January 5, 2023.
Each PSU represents a contingent right to receive one ordinary share of the Issuer.
On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 17, 2021, such performance criteria were met. Two-thirds of the ordinary shares subject to the PSUs vest on January 5, 2022 and the remaining one-third of the ordinary shares vest on January 5, 2023.
/s/ Miles W. McHugh, Attorney-in-Fact
2021-02-19